Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript
Cybin Inc. ( CYBN ) Q2 2026 Earnings Call November 13, 2025 8:00 AM EST Company Participants Eric So - Co-Founder, Interim CEO, President & Executive Chairman Amir Inamdar - Chief Medical Officer Greg Cavers - Chief Financial Officer George Tziras Conference Call Participants Sarah James Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Laura Suriel Eddie Hickman - Guggenheim Securities, LLC, Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Eric So Co-Founder, Interim CEO, President & Executive Chairman Good morning, and thank you for joining us.
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High?
The consensus price target hints at an 831.4% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Cybin Inc. (CYBN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet
The consensus price target hints at a 988.7% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 952.2% in Cybin Inc. (CYBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Cybin: Top Value Psychedelic Stock
Cybin is a promising value investment, with advanced clinical trials and strong institutional support, poised to disrupt mental health treatment. Cybin's proprietary drugs, CYB003 for depression and CYB004 for anxiety, show groundbreaking efficacy and shorter treatment time, enhancing patient and provider convenience. Cybin's trial results, robust IP portfolio, and solid financials de-risk its path to FDA approval, with a market cap significantly lower than competitors.
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
Cybin's CYB003 and CYB004 programs show promising results in treating depression and anxiety, with CYB003 achieving 75% remission in Phase 2 trials. Phase 3 trials, leveraging a strong IP portfolio and a streamlined operational structure.
3 Biotech Stocks That Could Make Your Summer Unforgettable
If you want to do well with biotech stocks, trade the anticipation of news. Look at Structure Therapeutics (NASDAQ: GPCR ), for example.
What Makes Cybin Inc. (CYBN) a New Buy Stock
Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cilo Cybin becomes first medical cannabis company to list in South Africa
South Africa's Cilo Cybin on Tuesday became the first medical cannabis company to list on the Johannesburg Stock Exchange's Alternative Exchange, as it hopes to capitalise on growth in the legal marijuana industry.
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
